MOMETASONE SUBSTIPHARM 50 micrograms/dose, suspension for spraying nasal bottle, 18 g
Active ingredients: Mometasone furoate, Mometasone furoate monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for sprayingbottle, 18 gnasale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MOMETASONE SUBSTIPHARM 50 microgrammes/dose, suspension pour pulvérisation nasale
- Pharmaceutical form
- suspension pour pulvérisation
- Route of administration
- nasale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 18 g (140 doses), avec pompe doseuse et applicateur nasal
- Marketing authorisation holder
- SUBSTIPHARM
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Apr 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60877018CIP73015134CIP133400930151341Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUROATE DE MOMÉTASONEsuspension | 50,00 microgrammes · une dose délivrée | FT |
| FUROATE DE MOMÉTASONE MONOHYDRATÉsuspension | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.